Single-versus multiple-fraction radiotherapy in patients with painful bone metastases: Cost-utility analysis based on a randomized trial

被引:170
作者
van den Hout, WB
van der Linden, YM
Steenland, E
Wiggenraad, RGJ
Kievit, J
de Haes, H
Leer, JWH
机构
[1] Leiden Univ, Med Ctr, Dept Med Decis Making, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Clin Oncol, NL-2300 RC Leiden, Netherlands
[3] Haaglanden Med Ctr, Dept Radiotherapy, The Hague, Netherlands
[4] Univ Amsterdam, Dept Psychol Med, Amsterdam, Netherlands
[5] Joint Ctr Radiat Oncol, Arnhem, Netherlands
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2003年 / 95卷 / 03期
关键词
D O I
10.1093/jnci/95.3.222
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases. Although single- and multiple-fraction radiotherapy are thought to provide equal palliation, which treatment schedule provides better value for the money is unknown. We compared quality-adjusted life expectancy (the overall valuation of the health of the patients) and societal costs for patients receiving either single- or multiple-fraction radiotherapy. Methods: A societal cost-utility analysis was performed on a Dutch randomized, controlled trial of 1157 patients with painful bone metastases that compared pain responses and quality of life from a single-fraction treatment schedule of 8 Gy with a treatment schedule of six fractions of 4 Gy each. The societal values of life expectancies were assessed with the EuroQol classification system (EQ-5D) questionnaire. A subset of 166 patients also answered additional questionnaires to estimate nonradiotherapy and nonmedical costs. Statistical tests were two-sided. Results: Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P = .20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P = .21). The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001). The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule, but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P = .06). For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (Pless than or equal to.05). Conclusions: Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands. Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.
引用
收藏
页码:222 / 229
页数:8
相关论文
共 29 条
[1]  
Ashton A, 1999, RADIOTHER ONCOL, V52, P111
[2]   Radiotherapeutic management of osseous metastases: A survey of current patterns of care [J].
Ben-Josef, E ;
Shamsa, F ;
Williams, AO ;
Porter, AT .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 40 (04) :915-921
[3]  
BLITZER PH, 1985, CANCER-AM CANCER SOC, V55, P1468, DOI 10.1002/1097-0142(19850401)55:7<1468::AID-CNCR2820550708>3.0.CO
[4]  
2-M
[5]   Thinking outside the box: Recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies [J].
Briggs, AH ;
O'Brien, BJ ;
Blackhouse, G .
ANNUAL REVIEW OF PUBLIC HEALTH, 2002, 23 :377-401
[6]  
Cole D J, 1989, Clin Oncol (R Coll Radiol), V1, P59, DOI 10.1016/S0936-6555(89)80035-4
[7]   Modeling valuations for EuroQol health states [J].
Dolan, P .
MEDICAL CARE, 1997, 35 (11) :1095-1108
[8]  
*DUTCH HLTH INS EX, 1999, PHARM COMP
[9]  
*DUTCH SOC RAD ONC, 2000, MAST RAD CAP SHORT S
[10]   Systematic overview of cost-utility assessments in oncology [J].
Earle, CC ;
Chapman, RH ;
Baker, CS ;
Bell, CM ;
Stone, PW ;
Sandberg, EA ;
Neumann, PJ .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (18) :3302-3317